Your session is about to expire
← Back to Search
Diagnostic Test
Liquid Biopsy for Lung Cancer
N/A
Waitlist Available
Led By Nathan Pennell, MD, PhD
Research Sponsored by Case Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up an average of 30 days
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to see if using blood tests can help start treatment sooner for patients with newly diagnosed lung cancer. The goal is to reduce the time it takes to begin treatment.
Who is the study for?
This trial is for new patients with advanced nonsquamous non-small cell lung cancer (NSCLC) who plan to receive systemic therapy and are referred to the Cleveland Clinic Taussig Cancer Center without prior genetic testing results. It's not open to those who've had previous treatment or adequate molecular testing for their current NSCLC diagnosis.
What is being tested?
The study is examining whether liquid biopsies can speed up the start of treatment in advanced NSCLC patients. A liquid biopsy involves taking a blood sample to search for cancer cells, which may help in quicker decision-making regarding therapy.
What are the potential side effects?
Since this trial focuses on diagnostic procedures rather than treatments, side effects are minimal and primarily related to blood draw complications like bruising, pain at the puncture site, or fainting.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ an average of 30 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~an average of 30 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
TTT measured in days
Secondary study objectives
Rate of actionable biomarker discovery
Rate of appropriate guideline-directed therapy based upon testing results
Time to actionable genetic testing results
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Liquid biopsyExperimental Treatment1 Intervention
A liquid biopsy is a test will be done on a sample of blood to look for cancer cells
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Liquid biopsy
2017
N/A
~210
Find a Location
Who is running the clinical trial?
Case Comprehensive Cancer CenterLead Sponsor
467 Previous Clinical Trials
32,555 Total Patients Enrolled
Nathan Pennell, MD, PhDPrincipal InvestigatorCleveland Clinic, Case Comprehensive Cancer Center
3 Previous Clinical Trials
35 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I plan to get my treatment at Cleveland Clinic or another site but will follow up or share my records with Cleveland Clinic.I have received treatment for non-small cell lung cancer before.You have already had the necessary genetic testing for your lung cancer diagnosis.I have advanced non-squamous NSCLC and was referred to the Cleveland Clinic without prior genetic testing results.
Research Study Groups:
This trial has the following groups:- Group 1: Liquid biopsy
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger